Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors
Tóm tắt
The combretastatins are a class of natural stilbenoids. These molecules generally share three common structural features: a trimethoxy "A"-ring, a "B"-ring containing substituent often at C3′ and C4′, and an ethene bridge between the two rings, which provides necessary structural rigidity. Members of the combretastatin family possess varying ability to cause vascular disruption in tumors. Combretastatin binds to the colchicine binding site of β-subunit of tubulin. Despite having a similar name, combretastatin is unrelated to statins, a family of cholesterol-lowering drugs. New combretastatin 2-(1-acetyl-1H-indole-3-yl)-3-(phenyl) propenoic analogues (2a to 2y), bearing indole moiety at the place of ring A of combretastatin (CA4), were synthesized and evaluated for anticancer activity against various cancer cell lines such as THP-1 (leukemia), A-549 (lung), IGROV-1 (ovary), HEP-2 (liver), MCF-7 (breast), and DU-145 (prostate). Compound 2d showed anti-cancer activity against THP-1 and MCF-7 with IC50 0.80 and 0.37 μM, respectively, and 2y showed against MCF-7 with IC50 3.60 μM comparable to paclitaxel. The target compounds bind to the colchicine binding site which is situated at α and β interface of tubulin and prevent polymerization as it was confirmed by immunofluorescence technique. The molecular docking further confirmed the binding of the potent compound 2d to the colchicine binding site at α and β interface of tubulin.
Tài liệu tham khảo
Jordan A, Hadfield JA, Lawrence NJ, McGown AT: Tubulin as a target for anticancer drugs: agent which interact with mitotic spindle. Inc Med Res Rev 1997, 18: 259–296.
Hadfield JA, Ducki S, Hirst N, McGown AT: Tubulin and microtubules as target for anticancer drugs. Progress in Cell Cycle Res 2003, 5: 309–325.
Meng F, Cai X, Duan J, Matteuccki MG, Hart CP: A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity. Canc Chemoth Pharmacol 2008, 61: 953–963. 10.1007/s00280-007-0549-x
Toso RJ, Jordan MA, Farrel KW, Matsumoto B, Wilson L: Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochem 1993, 32: 1285–1293. 10.1021/bi00056a013
Wu R, Ding W, Liu T, Zhu H, Hu Y, Yang B, He Q: XNO 5 , a novel synthesized microtubule inhibitor, exhibits potent activity against human carcinoma cells in vitro. Canc Lett 2009, 285: 13–22. 10.1016/j.canlet.2009.04.042
Mitchison T, Kirschner M: Dynamic instability of microtubule growth. Nature 1984, 312: 237–242. 10.1038/312237a0
Downing KH, Nogales E: New insights into microtubule structure and function from the atomic model of tubulin. Eur Biophys J 1998, 27: 431–436. 10.1007/s002490050153
Ouyang X, Piatnitski EL, Pattaropong V, Chen X, He HY, Kiselyov AS, Valankar A, Kwakami J, Labelle M, Smith L, Lohman J, Lee SP, Malikzay A, Fleming J, Gerlak J, Wang Y, Rosler RL, Zhou K, Mitelman S, Camara M, Surguladze D, Boody JF, Tuma MC: Oxadiazole derivatives as novel class of antimitotic agents: synthesis, inhibition of tubulin polymerization and activity in tumor cell lines. Bioorg Med Chem Lett 2006, 16: 1191–1196. 10.1016/j.bmcl.2005.11.094
Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA: Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem 2006, 49: 3033–3044. 10.1021/jm0512903
Woods JA, Hadfield JA, Pettit GR, Fox BW, McGown AT: The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Canc 1995, 71: 705–711. 10.1038/bjc.1995.138
McGown AT, Fox BW: Structural and biochemical comparison of the antimitotic agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des 1989, 3: 249–254.
Petit GR, Rhodes MR, Herald DL, Hamel E, Schmidt JM, Petit RK: Antineoplastic agents, 445, synthesis and evaluation of structural modifications of (Z), and (E)-combretastatin A-4. J Med Chem 2005, 48: 4087–4099. 10.1021/jm0205797
Kaffy J, Pontikis R, Carrz D, Croisy A, Monneret C, Florent JC: Isoxazole-type derivatives related to combretastatin A-4, synthesis and biological evaluation. Bioorg Med Chem 2006, 14: 4067–4077. 10.1016/j.bmc.2006.02.001
Pettit RK, Pettit GR, Hamel E, Hogan F, Moser BR, Wolf S, Pon S, Chapuis JC, Schmidt JM: E-combretastatin and E-resveratrol structural modifications: antimicrobial and cancer cell growth inhibitory β-E-nitrostyrenes. Bioorg Med Chem 2009, 17: 6606–6612. 10.1016/j.bmc.2009.07.076
Gupta S, Bhattacharyya B: Antimicrotubular drugs binding to vinca domain of tubulin. Mol Cell Biochem 2003, 253: 41–47. 10.1023/A:1026045100219
Cragg GM, Newman DJ: Ethnopharmacology. Oxford: EOLSS; 2006.
Cragg GM, Newman DJ: Anticancer agents from natural products. CRCnetBASE 2011, 2: 699–728.
Pinard PV, Wang F, Burd B, Angeletti RH, Horwitz SB, Orr GA: Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry. Biochem 2003, 42: 12019–12027. 10.1021/bi0350147
Enroth C, Eger BT, Okamoto K, Nishino T, Nishino T, Pai EF: Crystal structure of bovine milk xanthene dehydrogenase: structure based mechanism of conversion. Proc Natl Acad Sci USA 2000, 97: 10723. 10.1073/pnas.97.20.10723
Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M: Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004, 428: 198–202. 10.1038/nature02393
PerkinElmer, Inc: ChemDraw Ultra 6.0 and Chem3D Ultra. Cambridge, USA: Cambridge Soft Corporation; 2000.
CCDC: GOLD 5.0.1. Cambridge, UK: Cambridge Crystallographic Data Centre; 2011.
Cushman MS, Layfayette W, Hamel E: Stilbene derivatives as anticancer agents. 1995.
Leake PH: Synthesis of phenanthrene. Chem Rev 1956, 56: 27. 10.1021/cr50007a002
Sylvie D, Grant M, Ben G, Simon A, Jérémie FDC, Elizabeth B, Jim N, James P, Nicholas JL: Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones. Bioor Med Chem 2009, 17: 7711–7722. 10.1016/j.bmc.2009.09.044
Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Canc Inst 1991, 83: 757–766. 10.1093/jnci/83.11.757
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorometric cytotoxicity assay for anticancer-drug screening. J Natl Canc Inst 1990, 82: 1107–1112. 10.1093/jnci/82.13.1107